Health Care/Hospital

InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China

BEIJING, March 27, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA (National Medical Products Administration) for its TYK2 JH2 allosteric inhibitor ICP-488, which is the Compan...

2022-03-28 10:48 1549

Kintor Pharma Announces 2021 Business Progress and Annual Results

SUZHOU, China, March 25, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year endedDecember 3...

2022-03-26 01:23 7854

CCTV+: Peng Liyuan addresses World Tuberculosis Day video conference

BEIJING, March 24, 2022 /PRNewswire/ -- Peng Liyuan, wife of Chinese President Xi Jinping and World Health Organization (WHO) goodwill ambassador for Tuberculosis (TB) and HIV/AIDS, addressed the World Tuberculosis Day video conference on Thursday.   Global tuberculosis control...

2022-03-25 11:04 2055

Harbour BioMed Reports Full Year 2021 Financial Results: Empower Value Creation with Global Innovation Capabilities

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, March 24, 2022 /PRNewswire/ --Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology a...

2022-03-25 10:22 3095

CHINA LIFE INSURANCE COMPANY LIMITED ANNOUNCES 2021 ANNUAL RESULTS (H SHARES)

HONG KONG, March 24, 2022 /PRNewswire/ -- China Life Insurance Company Limited (SSE: 601628, SEHK: 2628, NYSE: LFC) announces the audited consolidated results of the Company (China Life Insurance Company Limited and its subsidiaries) for the year ended31 December 2021 (the "Reporting Period") pre...

2022-03-24 22:39 4472

New clinical trial collaboration for Cu-64 SAR-bisPSMA in prostate cancer

SYDNEY, March 24, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly...

2022-03-24 21:08 1867

Orion Health to deliver the world's largest health information exchange in Saudi Arabia

AUCKLAND, New Zealand, March 23, 2022 /PRNewswire/ -- Orion Health, the world's number one health data platform provider, has set another global benchmark by agreeing to build the world's largest health information exchange (HIE) for the Kingdom of Saudi Arabia.

2022-03-24 02:00 2375

CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, today announced that CT041, an autologous CAR T-cell product candidate against...

2022-03-23 20:50 1674

CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies

SHANGHAI, March 23, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2021 Annual Results. Business Highlights * CT053: complete...

2022-03-23 20:50 3263

Smartee Raises US$ 80 Million in Series D Funding

BEIJING, March 23, 2022 /PRNewswire/ -- In March 2022, Smartee announced that it has closed its Series D funding round ofUS$ 80 million. This round of financing was led by Beijing Taikang Investment, followed by China Resources Consumer Fund II, Jiaxing Science City, Zhangjiagang Industrial Inves...

2022-03-23 20:40 1576

Waterdrop Inc. Announces Fourth Quarter and Fiscal Year 2021 Unaudited Financial Results

BEIJING, March 23, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the fourth quarter and fiscal yea...

2022-03-23 15:40 3102

InnoCare Releases 2021 Annual Results and Business Highlights

BEIJING, March 22, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced 2021 annual results as of31 December 2021. Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, "We are delighted ...

2022-03-23 08:08 3046

VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease

SHANGHAI, March 22, 2022 /PRNewswire/ -- VivaVision Biotech, Inc. (VivaVision), an ophthalmic pharmaceutical developer focusing on discovery and development of innovative therapies for ocular diseases, today announced positive topline results from a Phase 2 clinical study of VVN001 in patients wi...

2022-03-23 08:00 1740

Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively

The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...

2022-03-23 06:53 3195

WuXi Biologics Achieved Record Growth and Profitability in 2021

Banner Year for Commercial Manufacturing Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million Adjusted Net Profit Rose by 100.3% to RMB3,435.9 Million Total Backlog Grew 20.1% to ...

2022-03-23 00:38 2845

INDICAID COVID-19 Rapid Antigen At-Home Test Receives FDA Emergency Use Authorization (EUA) for Over-the-Counter (OTC), Asymptomatic, Non- Prescription Use

GARDEN GROVE, Calif., March 22, 2022 /PRNewswire/ -- PHASE Scientific International, LTD  (PHASE Scientific), a high-growth biotech company founded by bioengineers fromUCLA, announces that its INDICAID® COVID-19 Rapid Antigen At-Home Test (INDICAID® OTC) recei...

2022-03-23 00:00 1891

Jacobio Announces Annual Results of 2021, R&D Investment Increases 83%

BEIJING and SHANGHAI and BOSTON, March 22, 2022 /PRNewswire/ -- Jacobio Announced its 2021 annual results on 22 March. As a clinical-stage biotech company, Jacobio's revenue wasRMB152 million, which was generated from an out-licensing deal. Its R&D investment wasRMB421 million, showing an increas...

2022-03-22 22:50 2260

IFF to Showcase Renewable Industrial Solutions and Polymer Portfolio at American Coatings Show

WILMINGTON, Del., March 22, 2022 /PRNewswire/ -- IFF's Industrial Solutions will bring its deep technical expertise, commitment to quality and broad portfolio of renewable polymers to theAmerican Coatings Show (ACS) for the first time on April 5-7.

2022-03-22 21:00 1864

NIBIOHN Identifies Tissue-specific Exosome Marker Candidates from Blood

OSAKA, Japan, March 22, 2022 /PRNewswire/ -- The National Institutes of Biomedical Innovation, Health and Nutrition (hereinafter NIBIOHN) based in Ibaraki-shi, Osaka Prefecture, has successfully catalogued more than 4,000 proteins contained in exosomes in healthy human blood (serum and plasma). Us...

2022-03-22 14:00 1349

OBiO Technology Goes Public on Shanghai Stock Exchange Today

SHANGHAI, March 22, 2022 /PRNewswire/ -- On March 22, 2022, OBiO Technology ( Shanghai) Corp., Ltd. ("OBiO" or "the Company"), has completed its initial public offering ("IPO") process and started trading on the Shanghai Stock Exchange's Sci-Tech innovation board (SSE, code: 688238). Founded in 2...

2022-03-22 13:00 2492
1 ... 166167168169170171172 ... 278